Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

27 Nov 2018 15:25

RNS Number : 6693I
GlaxoSmithKline PLC
27 November 2018
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

Previous balance: 33,863*

Restated balance: -27,669

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

575,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

547,331

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

*Due to clerical error the opening balance has been restated.

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

Previous balance: 2,693,951*

Restated balance: 2,755,483

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

532,131

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2,223,352

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

*Due to clerical error the opening balance has been restated.

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - ADS

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

7,909,994

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

573,898

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

7,336,096

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

827,306

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

5,000,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

154,683

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

5,672,623

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRZMMZMKNZGRZM
Date   Source Headline
16th Jul 202110:24 amRNSDirector/PDMR Shareholding
15th Jul 20211:21 pmRNSDirector/PDMR Shareholding
14th Jul 20213:34 pmRNSDirector/PDMR Shareholding
14th Jul 20213:17 pmRNSDirector/PDMR Shareholding
13th Jul 20219:44 amRNSDirector/PDMR Shareholding
13th Jul 20219:33 amRNSDirector/PDMR Shareholding
12th Jul 202110:23 amRNSDirector/PDMR Shareholding
12th Jul 202110:18 amRNSDirector/PDMR Shareholding
9th Jul 20219:30 amRNSDirector/PDMR Shareholding
2nd Jul 202112:36 pmRNSGSK and Alector collaboration in immuno-neurology
2nd Jul 202110:41 amRNSElliott Advisors (UK) letter to GSK
1st Jul 20212:29 pmRNSTotal Voting Rights
25th Jun 20214:54 pmRNSDirector/PDMR Shareholding
24th Jun 202111:07 amRNSDirector/PDMR Shareholding
23rd Jun 202111:00 amRNSGSK to deliver step-change in growth & performance
22nd Jun 20217:00 amRNSViiV/Halozyme sign exclusive licensing agreement
14th Jun 202111:58 amRNSGSK and iTeos announce collaboration for EOS-448
11th Jun 20214:54 pmRNSDirector/PDMR Shareholding
9th Jun 20213:28 pmRNSDirector/PDMR Shareholding
4th Jun 20214:02 pmRNSGSK recommend ADR holders reject mini-tender offer
1st Jun 202111:33 amRNSTotal Voting Rights
27th May 20219:21 amRNSDirector/PDMR Shareholding
27th May 20217:00 amRNSSanofi and GSK initiate new Phase 3 clinical study
27th May 20217:00 amRNSGSK/Vir Sotrovimab FDA Emergency Use Authorization
24th May 202110:10 amRNSDirector/PDMR Shareholding
21st May 202112:58 pmRNSGSK/VIR sotrovimab receives positive EMA opinion
18th May 20211:52 pmRNSBlock listing Interim Review
18th May 20217:00 amRNSMedicago/GSK COVID-19 Vaccine Positive Ph2 Results
17th May 20217:00 amRNSSanofi/GSK COVID-19 Vaccine Positive Ph2 Results
13th May 20214:46 pmRNSDirector/PDMR Shareholding
11th May 202112:54 pmRNSDirector/PDMR Shareholding
11th May 202111:30 amRNSEMTN Prospectus
6th May 20215:50 pmRNSBoard and Committee Changes
5th May 20216:23 pmRNSResult of AGM
4th May 20214:29 pmRNSTotal Voting Rights
28th Apr 20215:33 pmRNSDirector/PDMR Shareholding
28th Apr 202112:00 pmRNS1st Quarter Results
26th Apr 20214:14 pmRNSDirector/PDMR Shareholding
23rd Apr 20213:00 pmRNSEU approves GSK’s JEMPERLI (dostarlimab-gxly)
23rd Apr 20217:00 amRNSFDA approves GSK’s JEMPERLI (dostarlimab-gxly)
16th Apr 20214:00 pmRNSDirector/PDMR Shareholding
15th Apr 20213:21 pmRNSDirector/PDMR Shareholding
15th Apr 202110:17 amRNSDirector/PDMR Shareholding
14th Apr 20212:14 pmRNSDirector/PDMR Shareholding
14th Apr 202111:58 amRNSDirector/PDMR Shareholding
12th Apr 20215:32 pmRNSDirector/PDMR Shareholding
12th Apr 20219:48 amRNSDirector/PDMR Shareholding
9th Apr 20215:34 pmRNSDirector/PDMR Shareholding
9th Apr 20211:35 pmRNSDirector/PDMR Shareholding
6th Apr 20212:30 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.